Pulmonary Hypertension Related to Left Heart Disease (PH-LHD)

Strange, G.; Playford, D.; Stewart, S.; Deague, J.A.; Nelson, H.; Kent, A.; Gabbay, E. Pulmonary hypertension: Prevalence and mortality in the Armadale echocardiography cohort. Heart, 2012, 98(24), 1805-1811.
[http://dx.doi.org/10.1136/heartjnl-2012-301992] [PMID: 22760869]

Humbert, M.; Kovacs, G.; Hoeper, M.M.; Badagliacca, R.; Berger, R.M.F.; Brida, M.; Carlsen, J.; Coats, A.J.S.; Escribano-Subias, P.; Ferrari, P.; Ferreira, D.S.; Ghofrani, H.A.; Giannakoulas, G.; Kiely, D.G.; Mayer, E.; Meszaros, G.; Nagavci, B.; Olsson, K.M.; Pepke-Zaba, J.; Quint, J.K.; Rådegran, G.; Simonneau, G.; Sitbon, O.; Tonia, T.; Toshner, M.; Vachiery, J.L.; Vonk Noordegraaf, A.; Delcroix, M.; Rosenkranz, S. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J., 2023, 61(1), 2200879.
[http://dx.doi.org/10.1183/13993003.00879-2022] [PMID: 36028254]

Simonneau, G; Montani, D; Celermajer, DS Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. , 2019, 53(1), 1801913.
[http://dx.doi.org/10.1183/13993003.01913-2018]

Kovacs, G.; Berghold, A.; Scheidl, S.; Olschewski, H. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review. Eur. Respir. J., 2009, 34(4), 888-894.
[http://dx.doi.org/10.1183/09031936.00145608] [PMID: 19324955]

Al-Omary, M.S.; Sugito, S.; Boyle, A.J.; Sverdlov, A.L.; Collins, N.J. Pulmonary hypertension due to left heart disease: Diagnosis, pathophysiology, and therapy. Hypertension, 2020, 75(6), 1397-1408.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14330] [PMID: 32336230]

Maron, B.A.; Kovacs, G.; Vaidya, A.; Bhatt, D.L.; Nishimura, R.A.; Mak, S.; Guazzi, M.; Tedford, R.J. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. J. Am. Coll. Cardiol., 2020, 76(22), 2671-2681.
[http://dx.doi.org/10.1016/j.jacc.2020.10.007] [PMID: 33243385]

Palazzini, M.; Dardi, F.; Manes, A.; Bacchi Reggiani, M.L.; Gotti, E.; Rinaldi, A.; Albini, A.; Monti, E.; Galiè, N. Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC / ERS guidelines and insights for future changes. Eur. J. Heart Fail., 2018, 20(2), 248-255.
[http://dx.doi.org/10.1002/ejhf.860] [PMID: 28464427]

Caravita, S; Dewachter, C; Soranna, D Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: A meta-analysis. Eur Respir J., 2018, 51(4), 1702427.
[http://dx.doi.org/10.1183/13993003.02427-2017]

Vachiéry, J-L; Tedford, RJ; Rosenkranz, S Pulmonary hypertension due to left heart disease. Eur Respir J. , 2019, 53(1), 1801897.
[http://dx.doi.org/10.1183/13993003.01897-2018]

Weitsman, T.; Weisz, G.; Farkash, R.; Klutstein, M.; Butnaru, A.; Rosenmann, D.; Hasin, T. Pulmonary hypertension with left heart disease: Prevalence, temporal shifts in etiologies and outcome. Am. J. Med., 2017, 130(11), 1272-1279.
[http://dx.doi.org/10.1016/j.amjmed.2017.05.003] [PMID: 28552430]

Khush, K.K.; Tasissa, G.; Butler, J.; McGlothlin, D.; De Marco, T. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: Analysis of the evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE) database. Am. Heart J., 2009, 157(6), 1026-1034.
[http://dx.doi.org/10.1016/j.ahj.2009.02.022] [PMID: 19464413]

Thenappan, T.; Shah, S.J.; Gomberg-Maitland, M.; Collander, B.; Vallakati, A.; Shroff, P.; Rich, S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ. Heart Fail., 2011, 4(3), 257-265.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.958801] [PMID: 21411741]

Hart, S.A.; Krasuski, R.A.; Wang, A.; Kisslo, K.; Harrison, J.K.; Bashore, T.M. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J. Heart Valve Dis., 2010, 19(6), 708-715.
[PMID: 21214093]

Alexopoulos, D.; Lazzam, C.; Borrico, S.; Fiedler, L.; Ambrose, J.A. Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension. J. Am. Coll. Cardiol., 1989, 14(2), 319-322.
[http://dx.doi.org/10.1016/0735-1097(89)90180-0] [PMID: 2754121]

Raina, A.; Gertz, Z.M.; O’Donnell, W.T.; Herrmann, H.C.; Forfia, P.R. Pulmonary hypertension is a manifestation of congestive heart failure and left ventricular diastolic dysfunction in octogenarians with severe aortic stenosis. Pulm. Circ., 2015, 5(3), 521-526.
[http://dx.doi.org/10.1086/682226] [PMID: 26401253]

Assad, T.R.; Hemnes, A.R.; Larkin, E.K.; Glazer, A.M.; Xu, M.; Wells, Q.S.; Farber-Eger, E.H.; Sheng, Q.; Shyr, Y.; Harrell, F.E.; Newman, J.H.; Brittain, E.L. Clinical and biological insights into combined post-and pre-capillary pulmonary hypertension. J. Am. Coll. Cardiol., 2016, 68(23), 2525-2536.
[http://dx.doi.org/10.1016/j.jacc.2016.09.942] [PMID: 27931609]

Vanderpool, R.R.; Saul, M.; Nouraie, M.; Gladwin, M.T.; Simon, M.A. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol., 2018, 3(4), 298-306.
[http://dx.doi.org/10.1001/jamacardio.2018.0128] [PMID: 29541759]

Rosenkranz, S.; Gibbs, J.S.R.; Wachter, R.; De Marco, T.; Vonk-Noordegraaf, A.; Vachiéry, J.L. Left ventricular heart failure and pulmonary hypertension. Eur. Heart J., 2016, 37(12), 942-954.
[http://dx.doi.org/10.1093/eurheartj/ehv512] [PMID: 26508169]

Dupuis, J.; Guazzi, M. Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. Can. J. Cardiol., 2015, 31(4), 416-429.
[http://dx.doi.org/10.1016/j.cjca.2014.10.012] [PMID: 25840093]

Kapanci, Y.; Burgan, S.; Pietra, G.G.; Conne, B.; Gabbiani, G. Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am. J. Pathol., 1990, 136(4), 881-889.
[PMID: 2183626]

Guazzi, M.; Borlaug, B.A. Pulmonary hypertension due to left heart disease. Circulation, 2012, 126(8), 975-990.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.085761] [PMID: 22908015]

Fayyaz, A.U.; Edwards, W.D.; Maleszewski, J.J.; Konik, E.A.; DuBrock, H.M.; Borlaug, B.A.; Frantz, R.P.; Jenkins, S.M.; Redfield, M.M. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation, 2018, 137(17), 1796-1810.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031608] [PMID: 29246894]

Naeije, R.; Gerges, M.; Vachiery, J.L.; Caravita, S.; Gerges, C.; Lang, I.M. Hemodynamic phenotyping of pulmonary hypertension in left heart failure. Circ. Heart Fail., 2017, 10(9), e004082.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004082] [PMID: 28912263]

Tandon, H.D.; Kasturi, J. Pulmonary vascular changes associated with isolated mitral stenosis in India. Heart, 1975, 37(1), 26-36.
[http://dx.doi.org/10.1136/hrt.37.1.26] [PMID: 1111557]

Rosenkranz, S.; Howard, L.S.; Gomberg-Maitland, M.; Hoeper, M.M. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation, 2020, 141(8), 678-693.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022362] [PMID: 32091921]

Bosch, L.; Lam, C.S.P.; Gong, L.; Chan, S.P.; Sim, D.; Yeo, D.; Jaufeerally, F.; Leong, K.T.G.; Ong, H.Y.; Ng, T.P.; Richards, A.M.; Arslan, F.; Ling, L.H. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur. J. Heart Fail., 2017, 19(12), 1664-1671.
[http://dx.doi.org/10.1002/ejhf.873] [PMID: 28597497]

Tedford, R.J.; Hassoun, P.M.; Mathai, S.C.; Girgis, R.E.; Russell, S.D.; Thiemann, D.R.; Cingolani, O.H.; Mudd, J.O.; Borlaug, B.A.; Redfield, M.M.; Lederer, D.J.; Kass, D.A. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation, 2012, 125(2), 289-297.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.051540] [PMID: 22131357]

Uhley, H.N.; Leeds, S.E.; Sampson, J.J.; Friedman, M. Role of pulmonary lymphatics in chronic pulmonary edema. Circ. Res., 1962, 11(6), 966-970.
[http://dx.doi.org/10.1161/01.RES.11.6.966] [PMID: 13995239]

Barbieri, A.; Bursi, F.; Grigioni, F.; Tribouilloy, C.; Avierinos, J.F.; Michelena, H.I.; Rusinaru, D.; Szymansky, C.; Russo, A.; Suri, R.; Bacchi Reggiani, M.L.; Branzi, A.; Modena, M.G.; Enriquez-Sarano, M.; Tribouilloy, C.; Rusinaru, D.; Szymanski, C.; Fournier, A.; Trojette, F.; Touati, G.; Remadi, J.P.; Grigioni, F.; Russo, A.; Piovaccari, G.; Ferlito, M.; Ionico, T.; Barbaresi, E.; Branzi, A.; Savini, C.; Martin-Suarez, S.; Marinelli, G.; Di Bartolomeo, R.; Avierinos, J.F.; Tafanelli, L.; Habib, G.; Collard, F.; Riberi, A.; Metras, D.; Barbieri, A.; Bursi, F.; Grimaldi, T.; Nuzzo, A.; Modena, M.G.; Enriquez-Sarano, M.; Michelena, H.I.; Suri, R.; Bacchi-Reggiani, M.L. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: A multicenter long-term international study. Eur. Heart J., 2011, 32(6), 751-759.
[http://dx.doi.org/10.1093/eurheartj/ehq294] [PMID: 20829213]

Ratwatte, S.; Strange, G.; Playford, D.; Stewart, S.; Celermajer, D.S. Prevalence of pulmonary hypertension in mitral regurgitation and its influence on outcomes. Open Heart, 2023, 10(1), e002268.
[http://dx.doi.org/10.1136/openhrt-2023-002268] [PMID: 37280015]

Opitz, C.F.; Hoeper, M.M.; Gibbs, J.S.R.; Kaemmerer, H.; Pepke-Zaba, J.; Coghlan, J.G.; Scelsi, L.; D’Alto, M.; Olsson, K.M.; Ulrich, S.; Scholtz, W.; Schulz, U.; Grünig, E.; Vizza, C.D.; Staehler, G.; Bruch, L.; Huscher, D.; Pittrow, D.; Rosenkranz, S. Pre-capillary, combined, and post-capillary pulmonary hypertension: A pathophysiological continuum. J. Am. Coll. Cardiol., 2016, 68(4), 368-378.
[http://dx.doi.org/10.1016/j.jacc.2016.05.047] [PMID: 27443433]

Lee, F.; Mielniczuk, L.M. Pulmonary hypertension due to left heart disease—a practical approach to diagnosis and management. Can. J. Cardiol., 2021, 37(4), 572-584.
[http://dx.doi.org/10.1016/j.cjca.2020.11.003] [PMID: 33217522]

Tello, K.; Wan, J.; Dalmer, A.; Vanderpool, R.; Ghofrani, H.A.; Naeije, R.; Roller, F.; Mohajerani, E.; Seeger, W.; Herberg, U.; Sommer, N.; Gall, H.; Richter, M.J. Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ. Cardiovasc. Imaging, 2019, 12(9), e009047.
[http://dx.doi.org/10.1161/CIRCIMAGING.119.009047] [PMID: 31500448]

Gorter, T.M.; van Veldhuisen, D.J.; Voors, A.A.; Hummel, Y.M.; Lam, C.S.P.; Berger, R.M.F.; van Melle, J.P.; Hoendermis, E.S. Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur. Heart J. Cardiovasc. Imaging, 2018, 19(4), 425-432.
[http://dx.doi.org/10.1093/ehjci/jex133] [PMID: 28531295]

Guazzi, M.; Bandera, F.; Pelissero, G.; Castelvecchio, S.; Menicanti, L.; Ghio, S.; Temporelli, P.L.; Arena, R. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: An index of right ventricular contractile function and prognosis. Am. J. Physiol. Heart Circ. Physiol., 2013, 305(9), H1373-H1381.
[http://dx.doi.org/10.1152/ajpheart.00157.2013] [PMID: 23997100]

Reddy, Y.N.V.; Carter, R.E.; Obokata, M.; Redfield, M.M.; Borlaug, B.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation, 2018, 138(9), 861-870.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034646] [PMID: 29792299]

Ahmed, S.; Ahmed, A.; Rådegran, G. Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension. Int. J. Cardiol., 2021, 345, 68-76.
[http://dx.doi.org/10.1016/j.ijcard.2021.10.136] [PMID: 34710494]

Guazzi, M.; Bursi, F.; Rusconi, F. Lung biomarkers: A new route for distinguishing pulmonary hypertension due to HFpEF from pulmonary arterial hypertension. Int. J. Cardiol., 2022, 351, 91-92.
[http://dx.doi.org/10.1016/j.ijcard.2021.12.001] [PMID: 34915079]

Opotowsky, A.R.; Hess, E.; Maron, B.A.; Brittain, E.L.; Barón, A.E.; Maddox, T.M.; Alshawabkeh, L.I.; Wertheim, B.M.; Xu, M.; Assad, T.R.; Rich, J.D.; Choudhary, G.; Tedford, R.J. Thermodilution vs estimated Fick cardiac output measurement in clinical practice: An analysis of mortality from the veterans affairs clinical assessment, reporting, and tracking (VA CART) program and vanderbilt university. JAMA Cardiol., 2017, 2(10), 1090-1099.
[http://dx.doi.org/10.1001/jamacardio.2017.2945] [PMID: 28877293]

Herve, P.; Lau, E.M.; Sitbon, O.; Savale, L.; Montani, D.; Godinas, L.; Lador, F.; Jaïs, X.; Parent, F.; Günther, S.; Humbert, M.; Simonneau, G.; Chemla, D. Criteria for diagnosis of exercise pulmonary hypertension. Eur. Respir. J., 2015, 46(3), 728-737.
[http://dx.doi.org/10.1183/09031936.00021915] [PMID: 26022955]

Kovacs, G; Herve, P; Barbera, JA An official european respiratory society statement: Pulmonary haemodynamics during exercise. Eur Respir J., @017, 50(5), 1700578.
[http://dx.doi.org/10.1183/13993003.00578-2017]

Eisman, A.S.; Shah, R.V.; Dhakal, B.P.; Pappagianopoulos, P.P.; Wooster, L.; Bailey, C.; Cunningham, T.F.; Hardin, K.M.; Baggish, A.L.; Ho, J.E.; Malhotra, R.; Lewis, G.D. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ. Heart Fail., 2018, 11(5), e004750.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004750] [PMID: 29695381]

Hsu, S.; Brusca, S.B.; Rhodes, P.S.; Kolb, T.M.; Mathai, S.C.; Tedford, R.J. Use of thermodilution cardiac output overestimates diagnoses of exercise-induced pulmonary hypertension. Pulm. Circ., 2017, 7(1), 253-255.
[http://dx.doi.org/10.1086/690629] [PMID: 28680584]

Fujimoto, N.; Borlaug, B.A.; Lewis, G.D.; Hastings, J.L.; Shafer, K.M.; Bhella, P.S.; Carrick-Ranson, G.; Levine, B.D. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation, 2013, 127(1), 55-62.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.111302] [PMID: 23172838]

Andersen, M.J.; Olson, T.P.; Melenovsky, V.; Kane, G.C.; Borlaug, B.A. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ. Heart Fail., 2015, 8(1), 41-48.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001731] [PMID: 25342738]

Lewis, G.D.; Bossone, E.; Naeije, R.; Grünig, E.; Saggar, R.; Lancellotti, P.; Ghio, S.; Varga, J.; Rajagopalan, S.; Oudiz, R.; Rubenfire, M. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation, 2013, 128(13), 1470-1479.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.000667] [PMID: 24060943]

D’Alto, M.; Romeo, E.; Argiento, P.; Motoji, Y.; Correra, A.; Di Marco, G.M.; Iacono, A.M.; Barracano, R.; D’Andrea, A.; Rea, G.; Sarubbi, B.; Russo, M.G.; Naeije, R. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. Chest, 2017, 151(1), 119-126.
[http://dx.doi.org/10.1016/j.chest.2016.08.1439] [PMID: 27575357]

Borlaug, B.A. Invasive assessment of pulmonary hypertension: time for a more fluid approach? Circ. Heart Fail., 2014, 7(1), 2-4.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000983] [PMID: 24449809]

Fox, B.D.; Shimony, A.; Langleben, D.; Hirsch, A.; Rudski, L.; Schlesinger, R.; Eisenberg, M.J.; Joyal, D.; Hudson, M.; Boutet, K.; Serban, A.; Masetto, A.; Baron, M. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur. Respir. J., 2013, 42(4), 1083-1091.
[http://dx.doi.org/10.1183/09031936.00091212] [PMID: 23258775]

Robbins, I.M.; Hemnes, A.R.; Pugh, M.E.; Brittain, E.L.; Zhao, D.X.; Piana, R.N.; Fong, P.P.; Newman, J.H. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ. Heart Fail., 2014, 7(1), 116-122.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000468] [PMID: 24297689]

van de Bovenkamp, A.A.; Wijkstra, N.; Oosterveer, F.P.T.; Vonk Noordegraaf, A.; Bogaard, H.J.; van Rossum, A.C.; de Man, F.S.; Borlaug, B.A.; Handoko, M.L. The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction. Circ. Heart Fail., 2022, 15(4), e008935.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008935] [PMID: 35311526]

West, J.B.; Mathieu-Costello, O. Vulnerability of pulmonary capillaries in heart disease. Circulation, 1995, 92(3), 622-631.
[http://dx.doi.org/10.1161/01.CIR.92.3.622] [PMID: 7634477]

Cappola, T.P.; Felker, G.M.; Kao, W.H.L.; Hare, J.M.; Baughman, K.L.; Kasper, E.K. Pulmonary hypertension and risk of death in cardiomyopathy: Patients with myocarditis are at higher risk. Circulation, 2002, 105(14), 1663-1668.
[http://dx.doi.org/10.1161/01.CIR.0000013771.30198.82] [PMID: 11940544]

Ghio, S.; Gavazzi, A.; Campana, C.; Inserra, C.; Klersy, C.; Sebastiani, R.; Arbustini, E.; Recusani, F.; Tavazzi, L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J. Am. Coll. Cardiol., 2001, 37(1), 183-188.
[http://dx.doi.org/10.1016/S0735-1097(00)01102-5] [PMID: 11153735]

Clark, C.B.; Horn, E.M. Group 2 pulmonary hypertension: Pulmonary venous hypertension: epidemiology and pathophysiology. Cardiol. Clin., 2016, 34(3), 401-411.
[http://dx.doi.org/10.1016/j.ccl.2016.04.010] [PMID: 27443137]

Lam, C.S.P.; Roger, V.L.; Rodeheffer, R.J.; Borlaug, B.A.; Enders, F.T.; Redfield, M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J. Am. Coll. Cardiol., 2009, 53(13), 1119-1126.
[http://dx.doi.org/10.1016/j.jacc.2008.11.051] [PMID: 19324256]

Miller, W.L.; Grill, D.E.; Borlaug, B.A. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: Pulmonary hypertension and heart failure. JACC Heart Fail., 2013, 1(4), 290-299.
[http://dx.doi.org/10.1016/j.jchf.2013.05.001] [PMID: 24621932]

Hirashiki, A.; Kondo, T.; Adachi, S.; Nakano, Y.; Shimazu, S.; Shimizu, S.; Morimoto, R.; Okumura, T.; Murohara, T. Prognostic value of pulmonary hypertension in ambulatory patients with non-ischemic dilated cardiomyopathy. Circ. J., 2014, 78(5), 1245-1253.
[http://dx.doi.org/10.1253/circj.CJ-13-1120] [PMID: 24621657]

Assad, T.R.; Maron, B.A.; Robbins, I.M.; Xu, M.; Huang, S.; Harrell, F.E.; Farber-Eger, E.H.; Wells, Q.S.; Choudhary, G.; Hemnes, A.R.; Brittain, E.L. Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol., 2017, 2(12), 1361-1368.
[http://dx.doi.org/10.1001/jamacardio.2017.3882] [PMID: 29071338]

Maron, B.A.; Hess, E.; Maddox, T.M.; Opotowsky, A.R.; Tedford, R.J.; Lahm, T.; Joynt, K.E.; Kass, D.J.; Stephens, T.; Stanislawski, M.A.; Swenson, E.R.; Goldstein, R.H.; Leopold, J.A.; Zamanian, R.T.; Elwing, J.M.; Plomondon, M.E.; Grunwald, G.K.; Barón, A.E.; Rumsfeld, J.S.; Choudhary, G. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation, 2016, 133(13), 1240-1248.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020207] [PMID: 26873944]

Mohammed, S.F.; Hussain, I.; AbouEzzeddine, O.F.; Takahama, H.; Kwon, S.H.; Forfia, P.; Roger, V.L.; Redfield, M.M. Right ventricular function in heart failure with preserved ejection fraction: A community-based study. Circulation, 2014, 130(25), 2310-2320.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.008461] [PMID: 25391518]

Pellegrini, P.; Rossi, A.; Pasotti, M.; Raineri, C.; Cicoira, M.; Bonapace, S.; Dini, F.L.; Temporelli, P.L.; Vassanelli, C.; Vanderpool, R.; Naeije, R.; Ghio, S. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest, 2014, 145(5), 1064-1070.
[http://dx.doi.org/10.1378/chest.13-1510] [PMID: 24356904]

Al-Naamani, N.; Preston, I.R.; Paulus, J.K.; Hill, N.S.; Roberts, K.E. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail., 2015, 3(6), 467-474.
[http://dx.doi.org/10.1016/j.jchf.2015.01.013] [PMID: 26046840]

Pacher, R.; Stanek, B.; Hülsmann, M.; Koller-Strametz, J.; Berger, R.; Schuller, M.; Hartter, E.; Ogris, E.; Frey, B.; Heinz, G.; Mauerer, G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol., 1996, 27(3), 633-641.
[http://dx.doi.org/10.1016/0735-1097(95)00520-X] [PMID: 8606275]

Puri, S.; Baker, B.L.; Dutka, D.P.; Oakley, C.M.; Hughes, J.M.B.; Cleland, J.G.F. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation, 1995, 91(11), 2769-2774.
[http://dx.doi.org/10.1161/01.CIR.91.11.2769] [PMID: 7758183]

Hoeper, M.M.; Meyer, K.; Rademacher, J.; Fuge, J.; Welte, T.; Olsson, K.M. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail., 2016, 4(6), 441-449.
[http://dx.doi.org/10.1016/j.jchf.2015.12.016] [PMID: 26874383]

Olson, T.P.; Johnson, B.D.; Borlaug, B.A. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail., 2016, 4(6), 490-498.
[http://dx.doi.org/10.1016/j.jchf.2016.03.001] [PMID: 27256752]

Costard-Jäckle, A.; Fowler, M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J. Am. Coll. Cardiol., 1992, 19(1), 48-54.
[http://dx.doi.org/10.1016/0735-1097(92)90050-W] [PMID: 1729345]

Kieler-Jensen, N.; Lundin, S.; Ricksten, S-E. Vasodilator therapy after heart transplantation: Effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J. Heart Lung Transplant., 1995, 14(3), 436-443.
[PMID: 7654728]

Vonscheidt, W.; Costardjaeckle, A.; Stempfle, H.; Deng, M.; Schwaab, B.; Haaff, B.; Naegele, H.; Mohacsi, P.; Trautnitz, M. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: The PROPHET study. J. Heart Lung Transplant., 2006, 25(9), 1070-1076.
[http://dx.doi.org/10.1016/j.healun.2006.04.011] [PMID: 16962468]

Obokata, M.; Reddy, Y.N.V.; Melenovsky, V.; Pislaru, S.; Borlaug, B.A. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur. Heart J., 2019, 40(8), 689-697.
[http://dx.doi.org/10.1093/eurheartj/ehy809] [PMID: 30544228]

Clements, R.T.; Vang, A.; Fernandez-Nicolas, A.; Kue, N.R.; Mancini, T.J.; Morrison, A.R.; Mallem, K.; McCullough, D.J.; Choudhary, G. Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril/valsartan. Circ. Heart Fail., 2019, 12(11), e005819.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.005819] [PMID: 31707802]

Zern, E.K.; Cheng, S.; Wolfson, A.M.; Hamilton, M.A.; Zile, M.R.; Solomon, S.D.; Kittleson, M.M. Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation. Circ. Heart Fail., 2020, 13(2), e006696.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.006696] [PMID: 32059634]

Joki, Y.; Konishi, H.; Takasu, K.; Minamino, T. Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice. J. Cardiol., 2023, 81(4), 347-355.
[http://dx.doi.org/10.1016/j.jjcc.2022.10.003] [PMID: 36244565]

Nassif, M.E.; Qintar, M.; Windsor, S.L.; Jermyn, R.; Shavelle, D.M.; Tang, F.; Lamba, S.; Bhatt, K.; Brush, J.; Civitello, A.; Gordon, R.; Jonsson, O.; Lampert, B.; Pelzel, J.; Kosiborod, M.N. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: Results from the EMBRACE-HF trial. Circulation, 2021, 143(17), 1673-1686.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.052503] [PMID: 33550815]

Heidenreich, P.A.; Bozkurt, B.; Aguilar, D.; Allen, L.A.; Byun, J.J.; Colvin, M.M.; Deswal, A.; Drazner, M.H.; Dunlay, S.M.; Evers, L.R.; Fang, J.C.; Fedson, S.E.; Fonarow, G.C.; Hayek, S.S.; Hernandez, A.F.; Khazanie, P.; Kittleson, M.M.; Lee, C.S.; Link, M.S.; Milano, C.A.; Nnacheta, L.C.; Sandhu, A.T.; Stevenson, L.W.; Vardeny, O.; Vest, A.R.; Yancy, C.W. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J. Am. Coll. Cardiol., 2022, 79(17), e263-e421.
[http://dx.doi.org/10.1016/j.jacc.2021.12.012] [PMID: 35379503]

McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; Cleland, J.G.F.; Coats, A.J.S.; Crespo-Leiro, M.G.; Farmakis, D.; Gilard, M.; Heymans, S.; Hoes, A.W.; Jaarsma, T.; Jankowska, E.A.; Lainscak, M.; Lam, C.S.P.; Lyon, A.R.; McMurray, J.J.V.; Mebazaa, A.; Mindham, R.; Muneretto, C.; Francesco Piepoli, M.; Price, S.; Rosano, G.M.C.; Ruschitzka, F.; Kathrine Skibelund, A. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur. Heart J., 2021, 42(48), 4901.
[http://dx.doi.org/10.1093/eurheartj/ehab670] [PMID: 34649282]

Stevenson, L.W.; Tillisch, J.H. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation, 1986, 74(6), 1303-1308.
[http://dx.doi.org/10.1161/01.CIR.74.6.1303] [PMID: 3779915]

Johnson, W.; Omland, T.; Hall, C.; Lucas, C.; Myking, O.L.; Collins, C.; Pfeffer, M.; Rouleau, J.L.; Stevenson, L.W. Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol., 2002, 39(10), 1623-1629.
[http://dx.doi.org/10.1016/S0735-1097(02)01814-4] [PMID: 12020489]

Kutty, R.S.; Parameshwar, J.; Lewis, C.; Catarino, P.A.; Sudarshan, C.D.; Jenkins, D.P.; Dunning, J.J.; Tsui, S.S. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. Eur. J. Cardiothorac. Surg., 2013, 43(6), 1237-1242.
[http://dx.doi.org/10.1093/ejcts/ezs678] [PMID: 23345184]

Solomon, S.D.; McMurray, J.J.V.; Claggett, B.; de Boer, R.A.; DeMets, D.; Hernandez, A.F.; Inzucchi, S.E.; Kosiborod, M.N.; Lam, C.S.P.; Martinez, F.; Shah, S.J.; Desai, A.S.; Jhund, P.S.; Belohlavek, J.; Chiang, C.E.; Borleffs, C.J.W.; Comin-Colet, J.; Dobreanu, D.; Drozdz, J.; Fang, J.C.; Alcocer-Gamba, M.A.; Al Habeeb, W.; Han, Y.; Cabrera Honorio, J.W.; Janssens, S.P.; Katova, T.; Kitakaze, M.; Merkely, B.; O’Meara, E.; Saraiva, J.F.K.; Tereshchenko, S.N.; Thierer, J.; Vaduganathan, M.; Vardeny, O.; Verma, S.; Pham, V.N.; Wilderäng, U.; Zaozerska, N.; Bachus, E.; Lindholm, D.; Petersson, M.; Langkilde, A.M. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med., 2022, 387(12), 1089-1098.
[http://dx.doi.org/10.1056/NEJMoa2206286] [PMID: 36027570]

Obokata, M.; Kane, G.C.; Reddy, Y.N.V.; Melenovsky, V.; Olson, T.P.; Jarolim, P.; Borlaug, B.A. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur. Heart J., 2019, 40(45), 3707-3717.
[http://dx.doi.org/10.1093/eurheartj/ehz626] [PMID: 31513270]

Borlaug, B.A.; Kane, G.C.; Melenovsky, V.; Olson, T.P. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur. Heart J., 2016, 37(43), 3293-3302.
[http://dx.doi.org/10.1093/eurheartj/ehw241] [PMID: 27354047]

Gorter, T.M.; Obokata, M.; Reddy, Y.N.V.; Melenovsky, V.; Borlaug, B.A. Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur. Heart J., 2018, 39(30), 2825-2835.
[http://dx.doi.org/10.1093/eurheartj/ehy331] [PMID: 29947750]

Hoeper, M.M.; Lam, C.S.P.; Vachiery, J-L.; Bauersachs, J.; Gerges, C.; Lang, I.M.; Bonderman, D.; Olsson, K.M.; Gibbs, J.S.R.; Dorfmuller, P.; Guazzi, M.; Galiè, N.; Manes, A.; Handoko, M.L.; Vonk-Noordegraaf, A.; Lankeit, M.; Konstantinides, S.; Wachter, R.; Opitz, C.; Rosenkranz, S. Pulmonary hypertension in heart failure with preserved ejection fraction: A plea for proper phenotyping and further research. Eur. Heart J., 2017, 38(38), 2869-2873.
[PMID: 28011705]

Obokata, M.; Reddy, Y.N.V.; Pislaru, S.V.; Melenovsky, V.; Borlaug, B.A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation, 2017, 136(1), 6-19.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026807] [PMID: 28381470]

Reddy, Y.N.V.; Anantha-Narayanan, M.; Obokata, M.; Koepp, K.E.; Erwin, P.; Carter, R.E.; Borlaug, B.A. Hemodynamic effects of weight loss in obesity: A systematic review and meta-analysis. JACC Heart Fail., 2019, 7(8), 678-687.
[http://dx.doi.org/10.1016/j.jchf.2019.04.019] [PMID: 31302042]

Abraham, W.T.; Stevenson, L.W.; Bourge, R.C.; Lindenfeld, J.A.; Bauman, J.G.; Adamson, P.B. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial. Lancet, 2016, 387(10017), 453-461.
[http://dx.doi.org/10.1016/S0140-6736(15)00723-0] [PMID: 26560249]

Baumgartner, H.; Falk, V.; Bax, J.J.; Bonis, M.D.; Hamm, C.; Holm, P.J.; Iung, B.; Lancellotti, P.; Lansac, E.; Munoz, D.R.; Rosenhek, R.; Sjögren, J.; Mas, P.T.; Vahanian, A.; Walther, T.; Wendler, O.; Windecker, S.; Zamorano, J.L. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Kardiol. Pol., 2018, 76(1), 1-62.
[http://dx.doi.org/10.5603/KP.2018.0013] [PMID: 29399765]

Obadia, J.F.; Messika-Zeitoun, D.; Leurent, G.; Iung, B.; Bonnet, G.; Piriou, N.; Lefèvre, T.; Piot, C.; Rouleau, F.; Carrié, D.; Nejjari, M.; Ohlmann, P.; Leclercq, F.; Saint Etienne, C.; Teiger, E.; Leroux, L.; Karam, N.; Michel, N.; Gilard, M.; Donal, E.; Trochu, J.N.; Cormier, B.; Armoiry, X.; Boutitie, F.; Maucort-Boulch, D.; Barnel, C.; Samson, G.; Guerin, P.; Vahanian, A.; Mewton, N. Percutaneous repair or medical treatment for secondary mitral regurgitation. N. Engl. J. Med., 2018, 379(24), 2297-2306.
[http://dx.doi.org/10.1056/NEJMoa1805374] [PMID: 30145927]

Stone, G.W.; Lindenfeld, J.; Abraham, W.T.; Kar, S.; Lim, D.S.; Mishell, J.M.; Whisenant, B.; Grayburn, P.A.; Rinaldi, M.; Kapadia, S.R.; Rajagopal, V.; Sarembock, I.J.; Brieke, A.; Marx, S.O.; Cohen, D.J.; Weissman, N.J.; Mack, M.J. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med., 2018, 379(24), 2307-2318.
[http://dx.doi.org/10.1056/NEJMoa1806640] [PMID: 30280640]

Tigges, E.; Blankenberg, S.; von Bardeleben, R.S.; Zürn, C.; Bekeredjian, R.; Ouarrak, T.; Sievert, H.; Nickenig, G.; Boekstegers, P.; Senges, J.; Schillinger, W.; Lubos, E. Implication of pulmonary hypertension in patients undergoing MITRACLIP therapy: Results from the German transcatheter mitral valve interventions ( TRAMI ) registry. Eur. J. Heart Fail., 2018, 20(3), 585-594.
[http://dx.doi.org/10.1002/ejhf.864] [PMID: 29575435]

Al-Bawardy, R.; Vemulapalli, S.; Thourani, V.H.; Mack, M.; Dai, D.; Stebbins, A.; Palacios, I.; Inglessis, I.; Sakhuja, R.; Ben-Assa, E.; Passeri, J.J.; Dal-Bianco, J.P.; Yucel, E.; Melnitchouk, S.; Vlahakes, G.J.; Jassar, A.S.; Elmariah, S. Association of pulmonary hypertension with clinical outcomes of transcatheter mitral valve repair. JAMA Cardiol., 2020, 5(1), 47-56.
[http://dx.doi.org/10.1001/jamacardio.2019.4428] [PMID: 31746963]

Eleid, M.F.; Padang, R.; Pislaru, S.V.; Greason, K.L.; Crestanello, J.; Nkomo, V.T.; Pellikka, P.A.; Jentzer, J.C.; Gulati, R.; Sandhu, G.S.; Holmes, D.R., Jr; Nishimura, R.A.; Rihal, C.S.; Borlaug, B.A. Effect of transcatheter aortic valve replacement on right ventricular–pulmonary artery coupling. JACC Cardiovasc. Interv., 2019, 12(21), 2145-2154.
[http://dx.doi.org/10.1016/j.jcin.2019.07.025] [PMID: 31699376]

Shah, S.J.; Feldman, T.; Ricciardi, M.J.; Kahwash, R.; Lilly, S.; Litwin, S.; Nielsen, C.D.; van der Harst, P.; Hoendermis, E.; Penicka, M.; Bartunek, J.; Fail, P.S.; Kaye, D.M.; Walton, A.; Petrie, M.C.; Walker, N.; Basuray, A.; Yakubov, S.; Hummel, S.L.; Chetcuti, S.; Forde-McLean, R.; Herrmann, H.C.; Burkhoff, D.; Massaro, J.M.; Cleland, J.G.F.; Mauri, L. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: A randomized clinical trial. JAMA Cardiol., 2018, 3(10), 968-977.
[http://dx.doi.org/10.1001/jamacardio.2018.2936] [PMID: 30167646]

Shah, S.J.; Borlaug, B.A.; Chung, E.S.; Cutlip, D.E.; Debonnaire, P.; Fail, P.S.; Gao, Q.; Hasenfuß, G.; Kahwash, R.; Kaye, D.M.; Litwin, S.E.; Lurz, P.; Massaro, J.M.; Mohan, R.C.; Ricciardi, M.J.; Solomon, S.D.; Sverdlov, A.L.; Swarup, V.; van Veldhuisen, D.J.; Winkler, S.; Leon, M.B.; Akar, J.; Ando, J.; Anzai, T.; Asakura, M.; Bailey, S.; Basuray, A.; Bauer, F.; Bergmann, M.; Blair, J.; Cavendish, J.; Chung, E.; Cikes, M.; Dauber, I.; Donal, E.; Eicher, J-C.; Fail, P.; Flaherty, J.; Freixa, X.; Gafoor, S.; Gertz, Z.; Gordon, R.; Guazzi, M.; Guerrero-Miranda, C.; Gupta, D.; Gustafsson, F.; Hadadi, C.; Hakemi, E.; Handoko, L.; Hass, M.; Hausleiter, J.; Hayward, C.; Hickey, G.; Hummel, S.; Hussain, I.; Isnard, R.; Izumi, C.; Jondeau, G.; Juneman, E.; Kinugawa, K.; Kipperman, R.; Krakowiak, B.; Krim, S.; Larned, J.; Lewis, G.; Lipsic, E.; Magalski, A.; Mazimba, S.; Mazurek, J.; McGrady, M.; Mckenzie, S.; Mehta, S.; Mignone, J.; Morsli, H.; Nair, A.; Noel, T.; Orford, J.; Parikh, K.; Patterson, T.; Penicka, M.; Petrie, M.; Pieske, B.; Post, M.; Raake, P.; Romero, A.; Ryan, J.; Saito, Y.; Sakamoto, T.; Sakata, Y.; Samara, M.; Satya, K.; Sindone, A.; Starling, R.; Trochu, J-N.; Upadhya, B.; van der Heyden, J.; van Empel, V.; Varma, A.; Vest, A.; Wengenmayer, T.; Westenfeld, R.; Westermann, D.; Yamamoto, K.; Zirlik, A. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): A randomised, multicentre, blinded, sham-controlled trial. Lancet, 2022, 399(10330), 1130-1140.
[http://dx.doi.org/10.1016/S0140-6736(22)00016-2] [PMID: 35120593]

Selim, A.M.; Wadhwani, L.; Burdorf, A.; Raichlin, E.; Lowes, B.; Zolty, R. Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: A bridge to cure. Heart Lung Circ., 2019, 28(6), 946-952.
[http://dx.doi.org/10.1016/j.hlc.2018.04.299] [PMID: 29895486]

Martin, J.; Siegenthaler, M.; Friesewinkel, O.; Fader, T.; Vandeloo, A.; Trummer, G.; Berchtoldherz, M.; Beyersdorf, F. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation—a preliminary study1. Eur. J. Cardiothorac. Surg., 2004, 25(6), 971-977.
[http://dx.doi.org/10.1016/j.ejcts.2004.01.052] [PMID: 15144997]

Salzberg, S.P.; Lachat, M.L.; von Harbou, K.; Zünd, G.; Turina, M.I. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur. J. Cardiothorac. Surg., 2005, 27(2), 222-225.
[http://dx.doi.org/10.1016/j.ejcts.2004.11.001] [PMID: 15691674]

Potapov, E.; Meyer, D.; Swaminathan, M.; Ramsay, M.; El Banayosy, A.; Diehl, C.; Veynovich, B.; Gregoric, I.D.; Kukucka, M.; Gromann, T.W.; Marczin, N.; Chittuluru, K.; Baldassarre, J.S.; Zucker, M.J.; Hetzer, R. Inhaled nitric oxide after left ventricular assist device implantation: A prospective, randomized, double-blind, multicenter, placebo-controlled trial. J. Heart Lung Transplant., 2011, 30(8), 870-878.
[http://dx.doi.org/10.1016/j.healun.2011.03.005] [PMID: 21530317]

Murali, S.; Kormos, R.L.; Uretsky, B.F.; Schechter, D.; Reddy, P.S.; Denys, B.G.; Armitage, J.M.; Hardesty, R.L.; Griffith, B.P. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: The Pittsburgh experience. Am. Heart J., 1993, 126(4), 896-904.
[http://dx.doi.org/10.1016/0002-8703(93)90704-D] [PMID: 8213447]

Goland, S.; Czer, L.S.C.; Kass, R.M.; De Robertis, M.A.; Mirocha, J.; Coleman, B.; Capelli, C.; Raissi, S.; Cheng, W.; Fontana, G.; Trento, A. Pre-existing pulmonary hypertension in patients with end-stage heart failure: Impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. J. Heart Lung Transplant., 2007, 26(4), 312-318.
[http://dx.doi.org/10.1016/j.healun.2006.12.012] [PMID: 17403470]

Galiè, N.; Humbert, M.; Vachiery, J.L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Noordegraaf, A.V.; Beghetti, M.; Ghofrani, A.; Sanchez, M.A.G.; Hansmann, G.; Klepetko, W.; Lancellotti, P.; Matucci, M.; McDonagh, T.; Pierard, L.A.; Trindade, P.T.; Zompatori, M.; Hoeper, M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Kardiol. Pol., 2015, 73(12), 1127-1206.
[http://dx.doi.org/10.5603/KP.2015.0242] [PMID: 26727670]

Gerges, C.; Gerges, M.; Lang, M.B.; Zhang, Y.; Jakowitsch, J.; Probst, P.; Maurer, G.; Lang, I.M. Diastolic pulmonary vascular pressure gradient: A predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest, 2013, 143(3), 758-766.
[http://dx.doi.org/10.1378/chest.12-1653] [PMID: 23580984]

Naeije, R; Vachiery, J-L; Yerly, P The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J., 2016, 41(1), 217-223.
[http://dx.doi.org/10.1183/09031936.00074312]

Brittain, E.L.; Assad, T.R.; Hemnes, A.R.; Newman, J.H. The diastolic pressure gradient does not—and should not—predict outcomes. JACC Heart Fail., 2015, 3(10), 845.
[http://dx.doi.org/10.1016/j.jchf.2015.06.008] [PMID: 26450004]

Lewis, G.D.; Shah, R.; Shahzad, K.; Camuso, J.M.; Pappagianopoulos, P.P.; Hung, J.; Tawakol, A.; Gerszten, R.E.; Systrom, D.M.; Bloch, K.D.; Semigran, M.J. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation, 2007, 116(14), 1555-1562.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.716373] [PMID: 17785618]

Guazzi, M.; Vicenzi, M.; Arena, R.; Guazzi, M.D. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation, 2011, 124(2), 164-174.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.983866] [PMID: 21709061]

Hoendermis, E.S.; Liu, L.C.Y.; Hummel, Y.M.; van der Meer, P.; de Boer, R.A.; Berger, R.M.F.; van Veldhuisen, D.J.; Voors, A.A. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: A randomized controlled trial. Eur. Heart J., 2015, 36(38), 2565-2573.
[http://dx.doi.org/10.1093/eurheartj/ehv336] [PMID: 26188003]

Kramer, T.; Dumitrescu, D.; Gerhardt, F.; Orlova, K.; ten Freyhaus, H.; Hellmich, M.; Baldus, S.; Rosenkranz, S. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int. J. Cardiol., 2019, 283, 152-158.
[http://dx.doi.org/10.1016/j.ijcard.2018.12.078] [PMID: 30777406]

Cooper, T.J.; Cleland, J.G.F.; Guazzi, M.; Pellicori, P.; Ben Gal, T.; Amir, O.; Al-Mohammad, A.; Clark, A.L.; McConnachie, A.; Steine, K.; Dickstein, K. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SILHF study): A randomized placebo-controlled multicentre trial. Eur. J. Heart Fail., 2022, 24(7), 1239-1248.
[http://dx.doi.org/10.1002/ejhf.2527] [PMID: 35596935]

Bermejo, J.; Yotti, R.; García-Orta, R.; Sánchez-Fernández, P.L.; Castaño, M.; Segovia-Cubero, J.; Escribano-Subías, P.; San Román, J.A.; Borrás, X.; Alonso-Gómez, A.; Botas, J.; Crespo-Leiro, M.G.; Velasco, S.; Bayés-Genís, A.; López, A.; Muñoz-Aguilera, R.; de Teresa, E.; González-Juanatey, J.R.; Evangelista, A.; Mombiela, T.; González-Mansilla, A.; Elízaga, J.; Martín-Moreiras, J.; González-Santos, J.M.; Moreno-Escobar, E.; Fernández-Avilés, F.; Bermejo, J.; Yotti, R.; Mombiela, T.; Gónzález-Mansilla, A.; Elízaga, J.; García-Robles, J.A.; Pérez-David, E.; Pérez del Villar, C.; Sanz, R.; Gutierrez-Ibanes, E.; Vázquez, M.E.; Mur, A.; Benito, Y.; Martínez-Legazpi, P.; Barrio, A.; Vázquez, A.; García-Orta, R.; Uribe, I.; González, M.; Luis Sánchez, P.; González-Santos, J.M.; Martín-Moreiras, J.; Arribas, A.; Clemente Lorenzo, M.M.; Diego Nieto, A.; Castaño, M.; Pérez de Prado, A.; Alonso, D.; Segovia-Cubero, J.; Gómez-Bueno, M.; Sayago Silva, I.; Ángel Cavero, M.; Escribano-Subias, P.; Domínguez, L.; Tello de Meneses, R.; Ruiz Cano, M.J.; Jiménez López-Guarch, C.; San Román, J.A.; Mota, P.; Borrás, X.; Amorós Galitó, C.; Alonso-Gómez, A.; Belló Mora, M.C.; Mesa Rubio, D.; Botas, J.; Campuzano, R.; Crespo-Leiro, M.G.; Marzoa, R.; Cuenca, J.; Velasco, S.; Muñoz, R.; Suberviola, V.; Beltrán Herrera, C.; Mora, L.; Mar Sarrión, M.; Vaqueriza, D.; Bayes-Genís, A.; Ferrer, E.; González-Juanatey, J.R.; Cid, B.; Monzonís, A.M.; López, A.; Arizón de Prado, J.M.; Santisteban, M.; Mesa Rubio, D.; Evangelista, A.; García-Dorado, D.; de Teresa, E.; Jiménez-Navarro, M.; Carrasco Chinchilla, F.; Moreno-Escobar, E.; Alonso, J. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial. Eur. Heart J., 2018, 39(15), 1255-1264.
[http://dx.doi.org/10.1093/eurheartj/ehx700] [PMID: 29281101]

Frantz, R.P.; Desai, S.; Ewald, G.; Franco, V.; Hage, A.; Horn, E.M.; LaRue, S.J.; Mathier, M.A.; Mandras, S.A.; Park, M.H.; Ravichandran, A.; Wang, I.; Zolty, R.; Rocco, M.; Selej, M.; Zhao, C.; Rame, J. First results of soprano: Macitentan in patients (pts) with pulmonary hypertension (PH) post-left ventricular assist device (LVAD) implantation. J. Heart Lung Transplant., 2021, 40(4), S12-S13.
[http://dx.doi.org/10.1016/j.healun.2021.01.1767]

Tedford, R.J.; Hemnes, A.R.; Russell, S.D.; Wittstein, I.S.; Mahmud, M.; Zaiman, A.L.; Mathai, S.C.; Thiemann, D.R.; Hassoun, P.M.; Girgis, R.E.; Orens, J.B.; Shah, A.S.; Yuh, D.; Conte, J.V.; Champion, H.C. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ. Heart Fail., 2008, 1(4), 213-219.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.796789] [PMID: 19808294]

Gulati, G.; Grandin, E.W.; Kennedy, K.; Cabezas, F.; DeNofrio, D.D.; Kociol, R.; Rame, J.E.; Pagani, F.D.; Kirklin, J.K.; Kormos, R.L.; Teuteberg, J.; Kiernan, M. Preimplant phosphodiesterase-5 inhibitor use is associated with higher rates of severe early right heart failure after left ventricular assist device implantation: An INTERMACS analysis. Circ. Heart Fail., 2019, 12(6), e005537.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005537] [PMID: 31181953]

Vachiéry, J-L; Delcroix, M; Al-Hiti, H Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. , 51(2), 1701886.
[http://dx.doi.org/10.1183/13993003.01886-2017]

Packer, M.; McMurray, J.J.V.; Krum, H.; Kiowski, W.; Massie, B.M.; Caspi, A.; Pratt, C.M.; Petrie, M.C.; DeMets, D.; Kobrin, I.; Roux, S.; Swedberg, K.; Packer, M.; Caspi, A.; Kiowski, W.; Krum, H.; Pratt, C.; Swedberg, K.; Massie, B.; McMurray, J.; McMurray, J.; Connally, E.; Petrie, M.; DeMets, D.; Anderson, S.; Barnet, J.; Cody, R.; Dargie, H.; Francis, G.; Greenberg, B.; Reichen, J.; Karrasch, J.; Krum, H.; Horowitz, J.; Amerena, J.; Sindone, A.; MacDonald, P.; Jeffrey, I.; Button, I.; DeAngelis, E.; Pacher, R.; Davies, R.; McAlister, F.; Tanser, P.; Sussex, B.; Baumann, G.; Fleck, E.; Olbrich, H-G.; Werdan, K.; Klein, H.; Staffeld, F.; Zeiher, A.M.; Roediger, C.; Caspi, A.; Marmor, A.; Reisin, L.; Vered, Z.; Klainman, E.; Roguin, N.; Tzivoni, D.; David, D.; Lewis, B.; Abinader, E.; Omary, M.; Rosenman, Y.; Kaluski, E.; Breedveld, R.W.; van der Burgh, P.H.; Dunselman, P.H.J.M.; Schaafsma, H.J.; Hertzberger, D.P.; Holwerda, N.J.; Kragten, J.A.; van Wijngaarden, J.; Posma, J.L.; Said, S.A.M.; Slegers, L.C.; Tjon Joe Gin, R.M.; Wempe, F.N.; Wesdorp, J.C.L.; Willems, A.R.; Withagen, A.J.A.M.; Cornel, J.M.; van Kempen, L.H.J.; Kiowski, W.; Bertel, O.; Moccetti, T.; McMurray, J.J.V.; Greenbaum, R.A.; Bennett, P.; Swan, J.; Davies, G.; Findlay, I.; Gould, B.; Ball, S.; Hubner, P.; Lahiri, A.; McLay, J.; Northcote, R.; Saltissi, S.; Squire, I.; Stephens, J.; Stewart, M.; Bridgen, G.; Walsh, J.; Webb, D.J.; Ansari, Z.; Baron, S.; Bellinger, R.; Bennet, W.; Benvenuti, D.; Dawley, D.; Egbujiobi, L.C.; Eisenstein, I.; Little, T.; Hertsberg, A.; Greenspan, M.; Grossman, R.J.; Hanley, P.; Jesrani, M.; Kashou, H.; Levites, R.; Malik, R.; Marmorstein, B.; Schwartz, M.; Nisar, A.; Perelman, R.; Schwarz, M.L.; Sedlis, S.; Srebro, J.; Taveras, M.; Weiss, R.; Weitzman, P.; Wetherley, G.K.; El Shahawy, M.; Kereiakes, D.; Campos, L.; Peterson, G.; Small, R.S.; Davis, W.R.; Olivari, M-T.; Meengs, W.; Koren, M.; Slagona, P.; Jennison, S.; Hershberger, R.; Browne, K.F.; Farnham, D.J.; Zelenkofske, S.; Lawless, C.; Nathan, M.; Meyer, T.; Kukin, M.; Parekh, H.; Berkowitz, R.; Boehmer, J.; Brozena, S.; Dandona, P.; Dec, G.W.; DeQuattro, V.; Fenster, P.; Fowler, M.; Ellaham, S.; Geller, M.; Gheorgiade, M.; Ghali, J.; Murali, S.; Katz, S.; Bott-Silverman, C.; Singh, B.; Thadani, U.; Torre, G.; Teerlink, J.; Chandraratna, T.; Kesselbrenner, M.; Mukherjee, A.; Che-Pin Tsai, C.; Abbo, K.; Goldberg, M.; Smith, T.; Martin, R.T. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail., 2017, 5(5), 317-326.
[http://dx.doi.org/10.1016/j.jchf.2017.02.021] [PMID: 28449795]

Anand, I.; McMurray, J.; Cohn, J.N.; Konstam, M.A.; Notter, T.; Quitzau, K.; Ruschitzka, F.; Lüscher, T.F. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin a receptor antagonist trial in heart failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet, 2004, 364(9431), 347-354.
[http://dx.doi.org/10.1016/S0140-6736(04)16723-8] [PMID: 15276394]

Koller, B.; Steringer-Mascherbauer, R.; Ebner, C.H.; Weber, T.; Ammer, M.; Eichinger, J.; Pretsch, I.; Herold, M.; Schwaiger, J.; Ulmer, H.; Grander, W. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial). Heart Lung Circ., 2017, 26(5), 433-441.
[http://dx.doi.org/10.1016/j.hlc.2016.09.004] [PMID: 27816421]

Bonderman, D.; Ghio, S.; Felix, S.B.; Ghofrani, H.A.; Michelakis, E.; Mitrovic, V.; Oudiz, R.J.; Boateng, F.; Scalise, A.V.; Roessig, L.; Semigran, M.J. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation, 2013, 128(5), 502-511.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001458] [PMID: 23775260]

Gheorghiade, M.; Greene, S.J.; Butler, J.; Filippatos, G.; Lam, C.S.P.; Maggioni, A.P.; Ponikowski, P.; Shah, S.J.; Solomon, S.D.; Kraigher-Krainer, E.; Samano, E.T.; Müller, K.; Roessig, L.; Pieske, B. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA, 2015, 314(21), 2251-2262.
[http://dx.doi.org/10.1001/jama.2015.15734] [PMID: 26547357]

Pieske, B.; Maggioni, A.P.; Lam, C.S.P.; Pieske-Kraigher, E.; Filippatos, G.; Butler, J.; Ponikowski, P.; Shah, S.J.; Solomon, S.D.; Scalise, A.V.; Mueller, K.; Roessig, L.; Gheorghiade, M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: Results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J., 2017, 38(15), 1119-1127.
[http://dx.doi.org/10.1093/eurheartj/ehw593] [PMID: 28369340]

Armstrong, P.W.; Pieske, B.; Anstrom, K.J.; Ezekowitz, J.; Hernandez, A.F.; Butler, J.; Lam, C.S.P.; Ponikowski, P.; Voors, A.A.; Jia, G.; McNulty, S.E.; Patel, M.J.; Roessig, L.; Koglin, J.; O’Connor, C.M. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 2020, 382(20), 1883-1893.
[http://dx.doi.org/10.1056/NEJMoa1915928] [PMID: 32222134]

Armstrong, P.W.; Lam, C.S.P.; Anstrom, K.J.; Ezekowitz, J.; Hernandez, A.F.; O’Connor, C.M.; Pieske, B.; Ponikowski, P.; Shah, S.J.; Solomon, S.D.; Voors, A.A.; She, L.; Vlajnic, V.; Carvalho, F.; Bamber, L.; Blaustein, R.O.; Roessig, L.; Butler, J. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA, 2020, 324(15), 1512-1521.
[http://dx.doi.org/10.1001/jama.2020.15922] [PMID: 33079152]

Sueta, C.A.; Gheorghiade, M.; Adams, K.F., Jr; Bourge, R.C.; Murali, S.; Uretsky, B.F.; Pritzker, M.R.; McGoon, M.D.; Butman, S.M.; Grossman, S.H.; Crow, J.W.; Shaffer, C.L.; Thorn, M.D. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am. J. Cardiol., 1995, 75(3), 34A-43A.
[http://dx.doi.org/10.1016/S0002-9149(99)80381-6] [PMID: 7840053]

Califf, R.M.; Adams, K.F.; McKenna, W.J.; Gheorghiade, M.; Uretsky, B.F.; McNulty, S.E.; Darius, H.; Schulman, K.; Zannad, F.; Handberg-Thurmond, E.; Harrell, F.E., Jr; Wheeler, W.; Soler-Soler, J.; Swedberg, K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The flolan international randomized survival trial (FIRST). Am. Heart J., 1997, 134(1), 44-54.
[http://dx.doi.org/10.1016/S0002-8703(97)70105-4] [PMID: 9266782]

Oral treprostinil in subjects with pulmonary hypertension associated with heart failure with preserved ejection fraction. Available from: ClinicalTrials.gov

Slawsky, M.T.; Colucci, W.S.; Gottlieb, S.S.; Greenberg, B.H.; Haeusslein, E.; Hare, J.; Hutchins, S.; Leier, C.V.; LeJemtel, T.H.; Loh, E.; Nicklas, J.; Ogilby, D.; Singh, B.N.; Smith, W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation, 2000, 102(18), 2222-2227.
[http://dx.doi.org/10.1161/01.CIR.102.18.2222] [PMID: 11056096]

Hu, Y.; Wei, Z.; Zhang, C.; Lu, C.; Zeng, Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: A systematic review and meta-analysis. Sci. Rep., 2021, 11(1), 24097.
[http://dx.doi.org/10.1038/s41598-021-03317-5] [PMID: 34916560]

Zhang, H.; Wei, Y.; Zhang, C.; Yang, Z.; Kan, J.; Gu, H.; Fan, F.; Gu, H.; Wang, Q.; Xie, D.; Zhang, G.; Guo, X.; Yin, Y.; Jin, B.; Zhou, H.; Yang, Z.; Wang, Z.; Xin, Y.; Zhang, C.; Meng, L.; Wang, X.; Sun, J.; Zhao, C.; Zhang, J.; Yan, X.; Chen, F.; Yao, C.; Stone, G.W.; Chen, S.L. Pulmonary artery denervation for pulmonary arterial hypertension: A sham-controlled randomized PADN-CFDA trial. JACC Cardiovasc. Interv., 2022, 15(23), 2412-2423.
[http://dx.doi.org/10.1016/j.jcin.2022.09.013] [PMID: 36121246]

Zhang, H.; Yu, W.; Zhang, J. Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure. Pulm Circ., 2010, 9, 2045894018816297.
[http://dx.doi.org/10.1177/2045894018816297]